NDA 021431/S-013

SUPPLEMENT APPROVAL

Forest Laboratories, Inc.
Harborside Financial Center
Plaza V, Suite 1900
Jersey City, New Jersey 07311

Attention: David L. Urquhart
Senior Manager, Regulatory Affairs

Dear Mr. Urquhart:

Please refer to your Supplemental New Drug Application (sNDA) dated June 4, 2010, received June 7, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Campral (acamprosate calcium) Delayed-Release Tablets, 333 mg.

This “Changes Being Effected” supplemental new drug application provides for changes to the PRECAUTIONS section; Carcinogenicity, Mutagenicity and Impairment of Fertility subsection of the package insert to include language reflecting the conclusions from your postmarketing carcinogenicity study in mice, the final study results of which were submitted on July 30, 2009.

We have completed our review of this supplemental application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements and any annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Reference ID: 2876691
Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lisa E. Basham, Senior Regulatory Health Project Manager, at (301) 796-1175.

Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, MD  
Director  
Division of Anesthesia and Analgesia Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

**ENCLOSURE(S):**  
Content of Labeling

Reference ID: 2876691
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RIGOBERTO A ROCA on behalf of BOB A RAPPAPORT
12/13/2010